1. Home
  2. ABUS vs AROW Comparison

ABUS vs AROW Comparison

Compare ABUS & AROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Logo Arrow Financial Corporation

AROW

Arrow Financial Corporation

HOLD

Current Price

$37.50

Market Cap

727.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
AROW
Founded
2005
1851
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
836.0M
727.1M
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
ABUS
AROW
Price
$4.35
$37.50
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
★ $43.50
AVG Volume (30 Days)
★ 6.3M
54.3K
Earning Date
11-12-2026
11-02-2026
Dividend Yield
N/A
★ 3.26%
EPS Growth
★ 55.26
49.72
EPS
0.84
★ 1.48
Revenue
★ $14,083,000.00
N/A
Revenue This Year
$1,208.75
$24.57
Revenue Next Year
N/A
$16.41
P/E Ratio
★ $4.98
$25.05
Revenue Growth
★ 128.21
N/A
52 Week Low
$3.50
$26.17
52 Week High
$5.45
$42.70

Technical Indicators

Market Signals
Indicator
ABUS
AROW
Relative Strength Index (RSI) 35.56 46.89
Support Level $4.17 $35.74
Resistance Level $4.57 $37.88
Average True Range (ATR) 0.18 0.70
MACD -0.02 0.05
Stochastic Oscillator 15.43 62.33

Price Performance

Historical Comparison
ABUS
AROW

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About AROW Arrow Financial Corporation

Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.

Share on Social Networks: